{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:58Z","timestamp":1792177738901,"version":"4.4.0"},"reference-count":100,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1393,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1600-0404.2011.01601.x","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T07:01:25Z","timestamp":1320735685000},"page":"57-71","source":"Crossref","is-referenced-by-count":23,"special_numbering":"supplement s192","title":["Understanding and interpreting vision safety issues with vigabatrin therapy"],"prefix":"10.1155","volume":"124","author":[{"given":"G. T.","family":"Plant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.","family":"Sergott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,8]]},"reference":[{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB1|cit1","first-page":"731","article-title":"Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms","volume":"6","author":"Lerner","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/NDT.S5236","article-title":"Treatment of refractory complex partial seizures: role of vigabatrin","volume":"5","author":"Waterhouse","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0404.2011.01598.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major US trials","volume":"124","author":"Faught","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0404.2011.01597.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major European trials","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0404.2011.01599.x","article-title":"Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing","volume":"124","author":"Carmant","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study","volume":"38","author":"Vigevano","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1528-1157.1999.tb00802.x","article-title":"Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms","volume":"40","author":"Granstr\u00f6m","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14\u2003months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/01658100903582498","article-title":"Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin","volume":"34","author":"Sergott","year":"2010","journal-title":"Neuro-ophthalmology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.yebeh.2009.09.003","article-title":"Binasal visual field defects are not specific to vigabatrin","volume":"16","author":"Gonzalez","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrneurol.2011.25","article-title":"Epilepsy: vigabatrin treatment and visual field loss","volume":"7","author":"Chiron","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00023210-200115030-00005","article-title":"Visual field defects with vigabatrin: epidemiology and therapeutic implications","volume":"15","author":"K\u00e4lvi\u00e4inen","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1528-1167.2007.01133.x","article-title":"Vigabatrin and epilepsy: lessons learned","volume":"48","author":"Wild","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1535-7511.2009.01315.x","article-title":"Evaluating risks for vigabatrin treatment","volume":"9","author":"Krauss","year":"2009","journal-title":"Epilepsy Curr"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB21|cit21","first-page":"1","article-title":"Vigabatrin-associated visual field constriction: a review","volume":"7","author":"Lawden","year":"2006","journal-title":"Optometry Pract"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","article-title":"Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions","volume":"314","author":"Wilson","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0140-6736(05)79254-0","article-title":"Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents","volume":"352","author":"Baulac","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","article-title":"Visual field defects associated with vigabatrin therapy","volume":"67","author":"Lawden","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/jnnp.73.3.327","article-title":"The legacy of vigabatrin in a regional epilepsy clinic","volume":"73","author":"Nicolson","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","article-title":"Characteristics of a unique visual field defect attributed to vigabatrin","volume":"40","author":"Wild","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/seiz.2001.0544","article-title":"Reversed visual field constrictions in children after vigabatrin withdrawal - True retinal recovery or improved test performance only?","volume":"10","author":"Vanhatalo","year":"2001","journal-title":"Seizure"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1528-1157.2000.tb00212.x","article-title":"Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication","volume":"41","author":"Hardus","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1014644307518","article-title":"Visual field constriction and electrophysiological changes associated with vigabatrin","volume":"104","author":"Besch","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.eye.6700168","article-title":"Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal","volume":"16","author":"Newman","year":"2002","journal-title":"Eye (Lond)"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"K\u00e4lvi\u00e4inen","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB32|cit32","first-page":"185","article-title":"Visual field constriction and anti-epileptic drug treatment","volume":"7","author":"Stefan","year":"2000","journal-title":"Neurol Psychiatr Brain Res"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s004150200041","article-title":"Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study","volume":"249","author":"Schmitz","year":"2002","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","article-title":"Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings","volume":"53","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nurt.2006.11.008","article-title":"Vigabatrin","volume":"4","author":"Wheless","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/11317650-000000000-00000","article-title":"Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study","volume":"23","author":"Wild","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB37|cit37","article-title":"Assessing Retinal Toxicity of Vigabatrin and Other GABA-ergic Drugs in Patients with Epilepsy","volume":"47","author":"Gonzalez","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","article-title":"Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review","volume":"51","author":"Maguire","year":"2010","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.ophtha.2004.03.036","article-title":"Characteristic retinal atrophy with secondary \u201cinverse\u201d optic atrophy identifies vigabatrin toxicity in children","volume":"111","author":"Buncic","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/B:DOOP.0000005338.51554.e3","article-title":"Longitudinal changes in photopic OPs occurring with vigabatrin treatment","volume":"107","author":"Morong","year":"2003","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1014656626174","article-title":"The Hospital for Sick Children, Toronto, longitudinal ERG study of children on vigabatrin","volume":"104","author":"Westall","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:DOOP.0000005339.23258.8f","article-title":"Changes in the electroretinogram resulting from discontinuation of vigabatrin in children","volume":"107","author":"Westall","year":"2003","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2010.09.004","article-title":"Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy","volume":"92","author":"Sergott","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bjo.84.5.499","article-title":"A controlled study of vigabatrin and visual abnormalities","volume":"84","author":"Manuchehri","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1528-1157.2002.42001.x","article-title":"The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate","volume":"43","author":"Arndt","year":"2002","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2007.01249.x","article-title":"Visual field severity indices demonstrate dose- dependent visual loss from vigabatrin therapy","volume":"49","author":"Conway","year":"2008","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB47|cit47","unstructured":"Pellock JM Benefit\/risk considerations for Sabril \u00ae (vigabatrin)"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1528-1167.2006.00422.x","article-title":"Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose","volume":"47","author":"Kinirons","year":"2006","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.eye.6701405","article-title":"The natural history of vigabatrin associated visual field defects in patients electing to continue their medication","volume":"19","author":"Best","year":"2004","journal-title":"Eye"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1528-1157.2001.49299.x","article-title":"Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making","volume":"42","author":"Paul","year":"2001","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/eye.2009.64","article-title":"Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy","volume":"24","author":"Clayton","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/seiz.2000.0397","article-title":"Recovery of visual field constriction following discontinuation of vigabatrin","volume":"9","author":"Krakow","year":"2000","journal-title":"Seizure"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.67.6.707","article-title":"Vigabatrin associated visual field constriction","volume":"67","author":"Acheson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB54|cit54","first-page":"1694","article-title":"Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist","volume":"314","author":"Harding","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB55|cit55","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","author":"French","journal-title":"Ther Adv Drug Saf"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/seiz.2000.0381","article-title":"Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group","volume":"9","author":"Bruni","year":"2000","journal-title":"Seizure"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archneur.56.5.605","article-title":"Open comparative long-term study of vigabatrin vs. carbamazepine in newly diagnosed partial seizures in children","volume":"56","author":"Zamponi","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2011.01602.x","article-title":"Non-vision adverse events with vigabatrin therapy","volume":"124","author":"Walker","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","article-title":"Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss","volume":"55","author":"Harding","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ophtha.2008.09.047","article-title":"Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity","volume":"116","author":"Lawthom","year":"2009","journal-title":"Ophthalmology"},{"issue":"Suppl 7","key":"10.1111\/j.1600-0404.2011.01601.x-BIB61|cit61","first-page":"196","article-title":"Visual field defects in vigabatrin-treated children with epilepsy","volume":"41","author":"Rintahaka","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0404.2011.01600.x","article-title":"Primer on visual field testing methods and related algorithms for patients treated with vigabatrin","volume":"124","author":"Sergott","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ana.22266","article-title":"Retinal nerve fiber layer thickness in vigabatrin-exposed patients","volume":"69","author":"Clayton","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1167\/iovs.07-0738","article-title":"The relationship between visual field and retinal nerve fiber layer measurements in patients with multiple sclerosis","volume":"48","author":"Cheng","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/eye.2008.63","article-title":"Retinal nerve fiber layer thickness in patients with retinitis pigmentosa","volume":"23","author":"Oishi","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajo.2009.03.001","article-title":"Peripapillary retinal nerve fiber layer thinning in patients with autosomal recessive cone-rod dystrophy","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB67|cit67","unstructured":"Sergott RC Faught E Torrie S Wesche D Retinal structure and function in adult patients with refractory complex partial seizures treated with Sabril \u00ae (vigabatrin): an open-label, Phase IV study"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.52.6.1201","article-title":"Outer retinal dysfunction in patients treated with vigabatrin","volume":"52","author":"Arndt","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","article-title":"Symptomatic and asymptomatic visual loss in patients taking vigabatrin","volume":"106","author":"Daneshvar","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1034\/j.1600-0420.2000.078005580.x","article-title":"Visual field defects in patients taking vigabatrin","volume":"78","author":"Midelfart","year":"2000","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB71|cit71","first-page":"1104","article-title":"Visual field changes secondary to vigabatrin treatment [in Spanish]","volume":"31","author":"Mauri-Llerda","year":"2000","journal-title":"Rev Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1059-1311(00)90527-2","article-title":"Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake","volume":"10","author":"Toggweiler","year":"2001","journal-title":"Seizure"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.57.10.1916","article-title":"No reversion in vigabatrin-associated visual field defects","volume":"57","author":"Nousiainen","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1014679804792","article-title":"Vigabatrin and retinal changes","volume":"104","author":"Jensen","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1014615517996","article-title":"Visual field and electrophysiological abnormalities due to vigabatrin","volume":"104","author":"Van Der Torren","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/0883073810390213","article-title":"Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?","volume":"26","author":"McCoy","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB77|cit77","first-page":"477","article-title":"Visual field defect in a patient given sodium valproate then carbamazepine: possible effect of aminotransferase inhibition [in French]","volume":"158","author":"Jung","year":"2002","journal-title":"Rev Neurol (Paris)"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1468-1331.2007.01524.x","article-title":"Visual field defect during therapy with valproic-acid","volume":"14","author":"Tilz","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-2008-1050110","article-title":"Visual disorders caused by diphenylhydantoin: clinical and electro-ophthalmologic findings [in German]","volume":"192","author":"Lorenz","year":"1988","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/seiz.2001.0543","article-title":"Visual fields and tiagabine: a quandary","volume":"10","author":"Kaufman","year":"2001","journal-title":"Seizure"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/jnnp.2009.182378","article-title":"Hemispherical asymmetry in the Meyer\u2019s Loop: a prospective study of visual-field deficits in 105 cases undergoing anterior temporal lobe resection for epilepsy","volume":"81","author":"Jeelani","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1212\/WNL.57.2.196","article-title":"Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina","volume":"57","author":"Sills","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1528-1157.2003.04203.x","article-title":"Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina","volume":"44","author":"Sills","year":"2003","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/019262338701500203","article-title":"A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats","volume":"15","author":"Butler","year":"1987","journal-title":"Toxicol Pathol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00044011-200020060-00001","article-title":"Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine","volume":"20","author":"Nousiainen","year":"2000","journal-title":"Clin Drug Invest"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1167\/iovs.05-0854","article-title":"Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer","volume":"47","author":"Wild","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1034\/j.1600-0420.2003.00125.x","article-title":"Characterization of vigabatrin-associated optic atrophy","volume":"81","author":"Frisen","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1528-1157.2000.tb00117.x","article-title":"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction","volume":"41","author":"Harding","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/jnnp.70.6.787","article-title":"Visual field loss associated with vigabatrin: pathological correlations","volume":"70","author":"Ravindran","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB91|cit91","first-page":"47","article-title":"Retinal degeneration in cats fed casein. I. Taurine deficiency","volume":"15","author":"Schmidt","year":"1975","journal-title":"Invest Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1096\/fj.01-0691fje","article-title":"Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice","volume":"16","author":"Heller-Stilb","year":"2002","journal-title":"FASEB J"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02133668","article-title":"Amino acid transport through the blood-retinal and the blood-brain barrier","volume":"222","author":"Alm","year":"1985","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.bbamem.2008.04.012","article-title":"Function of taurine transporter (Slc6a6\/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells","volume":"1778","author":"Tomi","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM198501173120302","article-title":"Nutritional requirement for taurine in patients receiving long-term parenteral nutrition","volume":"312","author":"Geggel","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0896-6273(04)00141-2","article-title":"A role for ligand-gated ion channels in rod photoreceptor development","volume":"41","author":"Young","year":"2004","journal-title":"Neuron"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ana.21526","article-title":"Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity","volume":"65","author":"Jammoul","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.mcn.2010.01.008","article-title":"Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats","volume":"43","author":"Jammoul","year":"2010","journal-title":"Mol Cell Neurosci"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB99|cit99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brainres.2004.07.033","article-title":"The brain-to-blood efflux transport of taurine and changes in the blood-brain barrier transport system by tumor necrosis factor-alpha","volume":"1023","author":"Lee","year":"2004","journal-title":"Brain Res"},{"key":"10.1111\/j.1600-0404.2011.01601.x-BIB100|cit100","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2011.08.034","article-title":"Registry initiated to characterize vision loss associated with vigabatrin therapy","author":"Pellock","year":"2011","journal-title":"Epilepsy Behav"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2011.01601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2011.01601.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:49:42Z","timestamp":1671540582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2011.01601.x"}},"subtitle":["Vision safety issues with vigabatrin therapy"],"short-title":[],"issued":{"date-parts":[[2011,11,8]]},"references-count":100,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01601.x","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,8]]}}}